Home › Alcoholic Hepatitis › NCT07060547

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.

adult with a combined clinical diagnosis of alcohol-related liver disease (ALD) and nonalcoholic steatohepatitis (NASH).

Exclusion Criteria:

* Clinical diagnosis of liver disease with an etiology other than alcohol liver disease unless it is a combined clinical diagnosis of ALD and NASH.
* patients with solid organ malignancy.
* patients with other disease affecting the liver including autoimmune, drug-related liver injury, hemochromatosis or Wilson's disease
* pregnancy
* under the age of 18

About the study

This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.

What is being tested

• HepQuant DuO Test (device)

Sponsor: HepQuant, LLC · Participants: 40 · Started: Jun 10, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07060547

Locations in the U.S.

Conditions

• Alcoholic Hepatitis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.